Key Factor In Defensive Tackle's Release Opens Door For Cincinnati To Land Star ...

Dr. Frank Brodkey shares key insights from andexanet's development, approval, and real-world clinical trajectory.

President Donald Trump warned that Iran is working to develop missiles that could “soon reach U.S. territory,” raising ...

If Mars is a long-term dream, then the Moon is emerging as a strategic move and could be the key to realizing Elon Musk's ...

Bristol Myers Squibb and Johnson & Johnson have begun an educational campaign about the factor XIa pathway, laying the groundwork for a launch that could follow phase 3 readouts expected this year.

Background: Activated partial thromboplastin time (APTT) is the conventional test for monitoring unfractionated heparin (UFH) therapy, but discordance with anti-factor Xa results frequently occurs in ...

After today, andexanet alfa (Andexxa; AstraZeneca) will no longer be made or sold in the United States, according to an alert from the US Food and Drug Administration. The agency updated a safety ...

AstraZeneca will end U.S. commercial sales of Andexxa Dec. 22, citing safety concerns raised in postmarketing data and a recent trial, according to a Dec. 18 FDA news release. Andexxa, a recombinant ...

Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for today's call. [Operator Instructions] Please note that this ...

Table: Global Factor Xa Inhibitor Market (by Application), $Million, 2023-2035 Table: Global Factor Xa Inhibitor Market (by Route of Administration), $Million, 2023 ...